Madrigal Pharmaceuticals, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Madrigal Pharmaceuticals, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Madrigal Pharmaceuticals, Inc. do? Business model and key facts
Get the full picture of Madrigal Pharmaceuticals, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 915
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Stocks related to Madrigal Pharmaceuticals, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Madrigal Pharmaceuticals, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Madrigal Pharmaceuticals, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
